XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling

Abstract

SummaryHere we evaluated the epigenomic and transcriptomic profile of XPO1 mutant chronic lymphocytic leukaemia (CLL) and their clinical phenotype. By ATAC‐seq, chromatin regions that were more accessible in XPO1 mutated CLL were enriched of binding sites for transcription factors regulated by pathways emanating from the B‐cell receptor (BCR), including NF‐κB signalling, p38‐JNK and RAS‐RAF‐MEK‐ERK. XPO1 mutant CLL, consistent with the chromatin accessibility changes, were enriched with transcriptomic features associated with BCR and cytokine signalling. By combining epigenomic and transcriptomic data, MIR155HG, the host gene of miR‐155, and MYB, the transcription factor that positively regulates MIR155HG, were upregulated by RNA‐seq and their promoters were more accessible by ATAC‐seq. To evaluate the clinical impact of XPO1 mutations, we investigated a total of 957 early‐stage CLL subdivided into 3 independent cohorts (N = 276, N = 286 and N = 395). Next‐generation sequencing analysis identified XPO1 mutations as a novel predictor of shorter time to first treatment (TTFT) in all cohorts. Notably, XPO1 mutations maintained their prognostic value independent of the immunoglobulin heavy chain variable status and early‐stage prognostic models. These data suggest that XPO1 mutations, conceivably through increased miR‐155 levels, may enhance BCR signalling leading to higher proliferation and shorter TTFT in early‐stage CLL.